Cargando…
Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at le...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110893/ https://www.ncbi.nlm.nih.gov/pubmed/27882054 http://dx.doi.org/10.1155/2016/2138259 |
_version_ | 1782467765085405184 |
---|---|
author | Lee, Jeannette Y. Dhakal, Ishwori Casper, Corey Noy, Ariela Palefsky, Joel M. Haigentz, Missak Krown, Susan E. Ambinder, Richard F. Mitsuyasu, Ronald T. |
author_facet | Lee, Jeannette Y. Dhakal, Ishwori Casper, Corey Noy, Ariela Palefsky, Joel M. Haigentz, Missak Krown, Susan E. Ambinder, Richard F. Mitsuyasu, Ronald T. |
author_sort | Lee, Jeannette Y. |
collection | PubMed |
description | The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30–39, 40–49, 50–59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74–48.94), non-Hodgkin lymphoma (4.22; 3.63–4.45), Hodgkin lymphoma (9.83; 7.45–10.84), and anal cancer (30.54; 25.62–32.46) and lower for colorectal cancer (0.69; 0.52–0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45–0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers. |
format | Online Article Text |
id | pubmed-5110893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-51108932016-11-23 Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy Lee, Jeannette Y. Dhakal, Ishwori Casper, Corey Noy, Ariela Palefsky, Joel M. Haigentz, Missak Krown, Susan E. Ambinder, Richard F. Mitsuyasu, Ronald T. J Cancer Epidemiol Research Article The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30–39, 40–49, 50–59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74–48.94), non-Hodgkin lymphoma (4.22; 3.63–4.45), Hodgkin lymphoma (9.83; 7.45–10.84), and anal cancer (30.54; 25.62–32.46) and lower for colorectal cancer (0.69; 0.52–0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45–0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers. Hindawi Publishing Corporation 2016 2016-11-02 /pmc/articles/PMC5110893/ /pubmed/27882054 http://dx.doi.org/10.1155/2016/2138259 Text en Copyright © 2016 Jeannette Y. Lee et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lee, Jeannette Y. Dhakal, Ishwori Casper, Corey Noy, Ariela Palefsky, Joel M. Haigentz, Missak Krown, Susan E. Ambinder, Richard F. Mitsuyasu, Ronald T. Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy |
title | Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy |
title_full | Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy |
title_fullStr | Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy |
title_full_unstemmed | Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy |
title_short | Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy |
title_sort | risk of cancer among commercially insured hiv-infected adults on antiretroviral therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110893/ https://www.ncbi.nlm.nih.gov/pubmed/27882054 http://dx.doi.org/10.1155/2016/2138259 |
work_keys_str_mv | AT leejeannettey riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT dhakalishwori riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT caspercorey riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT noyariela riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT palefskyjoelm riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT haigentzmissak riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT krownsusane riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT ambinderrichardf riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy AT mitsuyasuronaldt riskofcanceramongcommerciallyinsuredhivinfectedadultsonantiretroviraltherapy |